JP2014503589A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503589A5
JP2014503589A5 JP2013551318A JP2013551318A JP2014503589A5 JP 2014503589 A5 JP2014503589 A5 JP 2014503589A5 JP 2013551318 A JP2013551318 A JP 2013551318A JP 2013551318 A JP2013551318 A JP 2013551318A JP 2014503589 A5 JP2014503589 A5 JP 2014503589A5
Authority
JP
Japan
Prior art keywords
amino
combination
amount
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013551318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503589A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/022638 external-priority patent/WO2012103276A1/en
Publication of JP2014503589A publication Critical patent/JP2014503589A/ja
Publication of JP2014503589A5 publication Critical patent/JP2014503589A5/ja
Pending legal-status Critical Current

Links

JP2013551318A 2011-01-26 2012-01-26 組合せ Pending JP2014503589A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161436435P 2011-01-26 2011-01-26
US61/436,435 2011-01-26
PCT/US2012/022638 WO2012103276A1 (en) 2011-01-26 2012-01-26 Combinations

Publications (2)

Publication Number Publication Date
JP2014503589A JP2014503589A (ja) 2014-02-13
JP2014503589A5 true JP2014503589A5 (enExample) 2015-03-19

Family

ID=46581159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013551318A Pending JP2014503589A (ja) 2011-01-26 2012-01-26 組合せ

Country Status (13)

Country Link
US (2) US20130296356A1 (enExample)
EP (1) EP2667871A4 (enExample)
JP (1) JP2014503589A (enExample)
KR (1) KR20140011322A (enExample)
CN (1) CN103476413B (enExample)
AU (1) AU2012209100A1 (enExample)
BR (1) BR112013018565A2 (enExample)
CA (1) CA2825790A1 (enExample)
EA (1) EA201391076A1 (enExample)
IL (1) IL227377A0 (enExample)
MX (1) MX2013008654A (enExample)
SG (1) SG191926A1 (enExample)
WO (1) WO2012103276A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404888SA (en) * 2012-02-17 2014-09-26 Pharmacyclics Inc Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
IN2015DN02667A (enExample) * 2012-10-12 2015-09-04 Glaxosmithkline Llc
AU2013334945A1 (en) * 2012-10-22 2015-04-23 Novartis Ag Combination
US20150306099A1 (en) * 2012-11-27 2015-10-29 Glaxosmithkline Llc Combination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034860B2 (en) * 2006-07-21 2011-10-11 Eastman Specialties Holdings Corporation Organosol plastisol compositions
EP2727909A1 (en) * 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
WO2010036796A1 (en) * 2008-09-26 2010-04-01 Concert Pharmaceuticals, Inc. Pyridineamine derivatives
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak

Similar Documents

Publication Publication Date Title
JP2012255026A5 (enExample)
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
JP2017504611A5 (enExample)
JP2015155440A5 (enExample)
JP2012515184A5 (enExample)
JP2016515628A5 (enExample)
JP2006504795A5 (enExample)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
CN111107848A (zh) 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
JP2012517449A5 (enExample)
JP2018530578A5 (enExample)
JP2020097577A5 (enExample)
JP2019530706A5 (enExample)
JP2014503589A5 (enExample)
JP2014526457A (ja) N−ヒドロキシ−4−{2−[3−(n,n−ジメチルアミノメチル)ベンゾフラン−2−イルカルボニルアミノ]エトキシ}ベンズアミドの投与に関するスキーム
RU2016103764A (ru) Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан
JP2016515550A5 (enExample)
JP2018039810A5 (enExample)
RU2018130097A (ru) Лечение экземы кистей
JP2013507382A5 (enExample)
JP2015512948A5 (enExample)
EA200600377A1 (ru) Новая композиция
MX2013008654A (es) Combinaciones.
JP2017514829A5 (enExample)
JP2017530142A5 (enExample)